Molecular structure of CAL-101, CAS Number: 870281-82-6
CAL-101 (CAS 870281-82-6)
See product citations (4)
Alternate Names:
Idelalisib; GS-1101
Application:
CAL-101 is a potent PI3K p110δ inhibitor
CAS Number:
870281-82-6
Purity:
≥98%
Molecular Weight:
415.42
Molecular Formula:
C22H18FN7O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CAL-101 is a compound utilized in various research disciplines, particularly in the study of signal transduction pathways. It acts as an inhibitor of the enzyme phosphoinositide 3-kinase p110δ (PI3Kδ), which is a critical component of the PI3K/Akt signaling pathway. Research involving CAL-101 primarily focuses on understanding the role of PI3Kδ in the modulation of cellular functions, such as cell growth, proliferation, and survival. Studies also explore how CAL-101 impacts immune cell function and signal transduction, providing insights into the regulation of immune responses. Additionally, the compound is of interest in cellular and molecular biology research to investigate the consequences of PI3Kδ inhibition on various cell types and the potential compensatory mechanisms that may be activated in response to this inhibition.
CAL-101 (CAS 870281-82-6) References
- Phosphatidylinositol 3-kinase-Δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. | Herman, SE., et al. 2010. Blood. 116: 2078-88. PMID: 20522708
- CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. | Lannutti, BJ., et al. 2011. Blood. 117: 591-4. PMID: 20959606
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. | Hoellenriegel, J., et al. 2011. Blood. 118: 3603-12. PMID: 21803855
- PI3KΔ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. | Meadows, SA., et al. 2012. Blood. 119: 1897-900. PMID: 22210877
- Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. | Xu, H., et al. 2013. Nature. 496: 523-7. PMID: 23619696
- Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells. | Nguyen, LX., et al. 2014. Blood Cancer J. 4: e228. PMID: 25014775
- Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. | Chiron, D., et al. 2014. Cancer Discov. 4: 1022-35. PMID: 25082755
- [Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs]. | Zhang, Q., et al. 2014. Zhonghua Xue Ye Xue Za Zhi. 35: 926-30. PMID: 25339332
- Endophilin marks and controls a clathrin-independent endocytic pathway. | Boucrot, E., et al. 2015. Nature. 517: 460-5. PMID: 25517094
- PI3kα and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization. | Mounayar, M., et al. 2015. Stem Cells. 33: 1892-901. PMID: 25753288
- Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress. | Park, GB., et al. 2015. Anticancer Res. 35: 2699-708. PMID: 25964548
- [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism]. | Qu, F., et al. 2015. Zhonghua Zhong Liu Za Zhi. 37: 412-7. PMID: 26463142
- Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth. | Qu, FL., et al. 2015. Cancer Biol Med. 12: 401-8. PMID: 26779377
- PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. | Safaroghli-Azar, A., et al. 2017. Anticancer Drugs. 28: 436-445. PMID: 28125433
- Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells. | Piazzi, M., et al. 2022. Molecules. 27: PMID: 35566091
Inhibitor of:
2900062L11Rik, 4930558K02Rik, 9330159F19Rik, ACAP2, AIDA, B Cell Marker, B lymphocytes, Bcl-11b, C1orf150, C230096C10Rik, CD32-C, CD79A, Clm3, CMTM7, DLD, DXBay18, DYNC2LI1, F8A2, FAM75C1, FcRH3, Gight chain, Gm9839, group IIE sPLA2, Hairy Cell Leukemia Marker, IBtk, Ig κ, Ig λ chain, IgD, IgD Chain, IgG light chain, IgH, IgH-VJ558, Igk-C, IgM, Lambda 5, LAT2, LAX1, LST1, Mig12, MLSN1, MS4A4A, MUM1, Olfr55, Olfr550, Olfr554, Olfr555, Olfr556, Olfr557, Olfr594, Olr1124, Olr1204, Olr1206, Olr1218, Olr1404, Olr1562, Olr157, Olr184, Olr309, Olr530, Olr592, Olr608, Olr707, Olr728, Olr749, Olr920, p13, Paired Box (PAX), Pax-5, Pellino 1, Pellino 2, PI 3-kinase, PI 3-kinase C2α, PI 3-kinase C2β, PI 3-kinase p100, PI 3-kinase p101, PI 3-kinase p110, PI 3-kinase p110 delta, PI 3-kinase p55γ, PI 3-kinase p85γ, PI 3-kinase p85110, PI 4-kinase II β, PIDD, PILR-β, Pinch-2, PIP2, PIP5KIII, PIPK II β, RASSF10, ROPN1, Shank 3, Siglec-G, SLA2, SNX31, STC2, SUR-5, TAPP1, TMEM55B, TPIP, TRIL, VpreB, VpreB1, YadA, and ZNF728.Activator of:
BCAP, Bcr, C030039L03Rik, CD77 synthase (A4GALT), EDRF1, MHC class IIβ, RSAD2, SHIP-1, and Tec.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CAL-101, 10 mg | sc-364453 | 10 mg | $189.00 |